Proteomika has announced an option agreement with Auguron Biosciences, Inc, giving them rights to exclusive access in two autoimmune disease areas to use Auguron’s Nucleic Acid Programmable Protein Array (NAPPA) technology.
NAPPA technology was developed at the Harvard Institute of Proteomics and is protected by several issued and pending patents, licensed exclusively to Auguron Biosciences. The technology enables fresh, functional proteins to be generated on high density microchips from surface printed DNA.
The Agreement allows Proteomika to manufacture and use NAPPA technology at Proteomika´s facilities for Proteomika´s internal purposes and the performance of services to partners.
At any time during the period, Proteomika may exercise the option to negotiate an exclusive license to NAPPA within the field of biomarker discovery pertaining to Inflammatory Bowel Disease and Lupus. Although the financial details were not disclosed, the companies have stated that the fundamental terms of the license are pre-agreed in the option.
“Having searched for quite some time, we realize NAPPA is the best choice in the proteomics horizon” said Laureano Simon, CEO of Proteomika. “For we want to explore the most powerful reservoir of biomarkers -the immune system.”
Auguron was formed in early 2007 to commercialize developments at the Harvard Institute for Proteomics (HIP). “Auguron is very excited about this agreement. It is the first disease-specific commercial venture for NAPPA and this option sets the stage for Proteomika to fully exploit the power of the platform in two very important disease areas” said Jim Richey, Co-Founder and Chief Executive of Auguron.
Proteomika´s CEO also commented: “NAPPA is the perfect complementary technology to Progenika´s expertise in Molecular Diagnostics, since we will be able to discover autoantibodies in a multiplex fashion. Lupus and IBD sufferers need better biomarkers for diagnosis, prognosis and drug response.”